Concepedia

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas, Marta Español‐Rego, Paula Rodríguez‐Otero, Juan Luis Reguera, Lucía López‐Corral, Beatriz Martín-Antonio, Aintzane Zabaleta, Susana Inogés,

The Lancet Oncology · 2023 · 87 citations · 15 references

DOIFull text

Open access

Concepts

References

15

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar, Meletios Α. Dimopoulos, Antonio Palumbo et al. · The Lancet Oncology · 2014 · 4.9K citations · Full text

, , +11

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

, , +17

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

, , +17

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

, , +17

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Sham Mailankody, Jeffrey Matous, Saurabh Chhabra et al. · Nature Medicine · 2023 · 241 citations

, , +17